Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 22327338
Anselmi F, et al. (2012) c-ABL modulates MAP kinases activation downstream of VEGFR-2 signaling by direct phosphorylation of the adaptor proteins GRB2 and NCK1. Angiogenesis 15, 187-97 22327338
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
LY294002 VEGF inhibit treatment-induced increase

Y221-p - CRK (human)
Modsite: GGPEPGPyAQPsVNt SwissProt Entrez-Gene
Orthologous residues
CRK (human): Y221‑p, CRK iso2 (human): , CRK (mouse): Y221‑p, CRK iso3 (mouse): , CRK (rat): Y221‑p, CRK (chicken): Y222‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
LY294002 VEGF inhibit treatment-induced increase

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
imatinib VEGF increase
VEGF increase
LY294002 VEGF increase
VEGF Abl (human) decrease Abl -/- increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
imatinib VEGF increase
VEGF increase
LY294002 VEGF increase
VEGF Abl (human) decrease Abl -/- increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
imatinib VEGF increase
VEGF increase
LY294002 VEGF increase
VEGF Abl (human) decrease Abl -/- increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
imatinib VEGF increase
VEGF increase
LY294002 VEGF increase
VEGF Abl (human) decrease Abl -/- increase

Y209-p - GRB2 (human)
Modsite: TGMFPRNyVtPVNrN SwissProt Entrez-Gene
Orthologous residues
GRB2 (human): Y209‑p, GRB2 iso2 (human): Y168‑p, GRB2 (mouse): Y209‑p, GRB2 (rat): Y209‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
imatinib VEGF increase
VEGF increase
LY294002 VEGF increase
VEGF Abl (human) decrease Abl -/- increase

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
imatinib VEGF increase
VEGF increase
LY294002 VEGF increase
VEGF Abl (human) decrease Abl -/- increase

Y105-p - NCK1 (human)
Modsite: VDPGERLyDLNMPAy SwissProt Entrez-Gene
Orthologous residues
NCK1 (human): Y105‑p, NCK1 iso2 (human): Y41‑p, NCK1 (mouse): Y105‑p, NCK1 (rat): Y105‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Abl (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Abl (human) mutation in upstream enzyme recognition motif, transfection of constitutively active enzyme, activation of upstream enzyme

T180-p - P38A (human)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
imatinib VEGF increase
VEGF increase
LY294002 VEGF increase
VEGF increase
VEGF NCK1 (human) augment treatment-induced increase Nck1 Y105F mutant
VEGF Abl (human) decrease Abl -/- increase

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
VEGF increase
imatinib VEGF increase
VEGF increase
LY294002 VEGF increase
VEGF increase
VEGF NCK1 (human) augment treatment-induced increase Nck1 Y105F mutant
VEGF Abl (human) decrease Abl -/- increase

Y951-p - VEGFR2 (human)
Modsite: RFRQGKDyVGAIPVD SwissProt Entrez-Gene
Orthologous residues
VEGFR2 (human): Y951‑p, VEGFR2 (mouse): Y949‑p, VEGFR2 (rat): Y947‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human